Itamar Medical Reports First Quarter 2021 Results

First Quarter 2021 Revenues Increase 43% to $12.0 Million
U.S. WatchPAT™ Revenues Increase 38% to $8.4 Million
Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT

CAESAREA, Israël, 19 mei 2021 (GLOBE NEWSWIRE) - Itamar Medical B.V. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the first quarter of 2021.

“We were pleased to see the momentum from the second half of 2020 continue into new year, enabling us to achieve record first quarter revenue. Our U.S. core sleep business was once again the primary growth driver as home-based care continued to drive adoption and our Cardiology tests reached all-time high,” said Gilad Glick, President and Chief Executive Officer. “Overall, demand for WatchPAT is increasing worldwide, reflecting positive reception to our paradigm-shifting technology. Even as COVID restrictions began lifting, providing an opportunity for PSG testing in sleep centers to return, our sales remained strong.”

“Itamar has a number of exciting catalysts ahead and importantly, we have a significantly strengthened balance sheet in place to deliver on these initiatives. Our team remains focused on driving global market share, advancing our product portfolio, and pursuing additional in-organic growth opportunities,” concluded Glick.

First Quarter 2021 Highlights and Recent Achievements

Total revenues were $12.0 million, an increase of 43% year-over-year.

U.S. WatchPAT revenues were $8.4 million, an increase of 38% year-over-year.

Gained a total of 725 WatchPAT ONE customers since April 1, 2020, after continuing to onboard approximately 32 new WatchPAT ONE customers per month on average throughout the first quarter.

Non-IFRS gross margin was 72%, compared to 71% in the fourth quarter of 2020 and 77% in the first quarter of 2020. (See “Use of Non-IFRS Measures” below).

IFRS operating expenses include $1.1 million relating to non-recurring share-based payments resulting from the extended exercise period of vested service options from five to ten years.

Announced the expected launch of three additions to the Company’s WatchPAT product line at the upcoming SLEEP 2021 meeting.

Financiële resultaten eerste kwartaal 2021

Revenues increased 43% to $12.0 million, compared to $8.4 million in the same quarter in 2020. Revenue growth was mainly driven by an increase in WatchPAT sales in the U.S., and the increase in total sales in Japan and Europe.

WatchPAT revenues increased 33% to $10.9 million, compared to $8.2 million in the same quarter in 2020.

U.S. WatchPAT revenues increased 38% to $8.4 million, compared to $6.1 million in the same quarter in 2020, driven primarily by WatchPAT ONE sales, as well as WatchPAT Direct sales. Sales from disposables and renewable products, including WatchPAT ONE, comprised approximately 79% of WatchPAT revenues in the U.S. in the first quarter of 2021, compared to 75% in the same quarter in 2020.

Gross profit increased to $8.0 million, compared to $6.3 million in the same quarter in 2020. Gross margin decreased to 67%, compared to 76% in the same quarter in 2020. Gross margin decline was mainly driven by the increase in WatchPAT ONE sales, as well as non-recurring expenses of $0.4 million related to relocating the Company’s production facilities to a new location during the first quarter of 2021. Non-IFRS gross margin (see “Reconciliation of IFRS to Non-IFRS Financial Measures” below) decreased to 72%, compared to 77% in the same quarter in 2020. Non-IFRS gross margin decline was mainly driven by the increase in WatchPAT ONE sales. (See “Use of Non-IFRS Measures” below).

Operating loss was $5.3 million, compared to $2.0 million in the same quarter in 2020. The increase in operating loss was primarily due to an increase in operating expenses, partially offset by the increase in revenues. Operating expense increase was mainly driven by the following:

-		$1.1 million relating to non-recurring share-based payments resulting from the extension of the exercise period of vested service options from five to ten years.

-		Selling and marketing expenses increased 39% to $7.3 million, compared to $5.3 million in the same quarter in 2020, due to the planned expansion of the U.S. sales team into new geographical territories and verticals (37 territories and verticals as of March 31, 2021, compared to 32 territories and verticals as of March 31, 2020), as well as additional sales commissions resulting from the increase in revenues, increase in consulting fees relating to reimbursement in the U.S., Australia and Japan, and an increase in share-based payments, as mentioned above.

-		Research and development expenses increased 122% to $2.9 million, compared to $1.3 million in the same quarter in 2020, driven by expenses of $0.8 million associated with research and development of the Remote Patient Monitoring or RPM technology (including amortization of intangible assets of $0.3 million) associated with the Spry acquisition, an increase in personnel to support product development, mainly related to our digital health platform, and an increase in share-based payments, as mentioned above.

-		General and administrative expenses increased 80% to $3.1 million, compared to $1.7 million in the same quarter in 2020, mainly driven by an increase in directors’ and officers’ insurance premium, as well as increased legal expenses, including a commercial dispute in defense of our intellectual property initiated by the Company, and an increase in share-based payments, as mentioned above.

Non-IFRS operating loss (see “Reconciliation of IFRS to Non-IFRS Financial Measures” below) for the first quarter of 2021 was $2.8 million, compared to $1.4 million in the same quarter in 2020. Non-IFRS operating loss excludes approximately $2.5 million in share-based payments; depreciation and amortization of property and equipment and intangible assets; change in provision for doubtful and bad debt; and non-recurring expenses related to relocating our production facilities to a new location, compared to a total of $0.6 million of similar expenses for the same quarter in 2020. (See “Use of Non-IFRS Measures” below).

Net loss for the first quarter of 2021 was $5.5 million, compared to $2.0 million in the same quarter in 2020.

Non-IFRS net loss (see “Reconciliation of IFRS to Non-IFRS Financial Measures” below) for the first quarter of 2021 was $3.0 million, compared to $1.4 million in the same quarter in 2020. Non-IFRS net loss excludes approximately $2.5 million in share-based payments; depreciation and amortization of property and equipment and intangible assets; change in provision for doubtful and bad debt; and non-recurring expenses related to relocating the Company’s production facilities to a new location, compared to a total of $0.6 million of similar expenses for the same quarter in 2020. (See “Use of Non-IFRS Measures” below).

Loss per ADS (basic and diluted) for the first quarter of 2021 was $0.36 compared to $0.15 in the same quarter in 2020. Non-IFRS loss per ADS (basic and diluted) (see “Reconciliation of IFRS to Non-IFRS Financial Measures” below) for the first quarter of 2021 was $0.20, compared to $0.11 in the same quarter in 2020. (See “Use of Non-IFRS Measures” below).

As of March 31, 2021, the Company had cash, cash equivalents and short-term bank deposits of $78.9 million.

leiding

Full year 2021 revenue is still expected to be in the range of $52 to $53 million, representing growth of 27% to 29% over full year 2020 revenue.

Lease Agreement – Caesarea Headquarters

The Company entered into a new lease agreement, replacing the current agreement, for the lease of approximately 12,500 square feet of office space, as of January 1, 2022, for the Company’s headquarters, research, development and sales offices, in the Northern Caesarea Business Park, Caesarea, Israel.

Conference Call en Webcast-informatie

The Company will host a conference call today at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update.

Ga naar om live via webcast te luisteren https://www.itamar-medical.com/, Of hier te klikken.

To participate via phone, please use the dial in information:

U.S. toll-free: 833-519-1272
Internationaal: 914-800-3844
Israël gratis: 1-809-315-362
Conferentie-ID: 9398218

Please log in approximately 10 minutes prior to the scheduled start time. An archived webcast also will be provided in the Events and Presentations section of the Company’s website.

Gebruik van niet-IFRS-maatstaven

In addition to disclosing financial results prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board (IASB), this press release contains Non-IFRS financial measures for operating loss and net loss, which are adjusted from results based on IFRS to exclude: (i) share-based payments; (ii) depreciation and amortization of property and equipment and intangible assets; (iii) change in provision for doubtful and bad debt; and (iv) non-recurring expenses related to relocating production facilities to a new location. Management believes that the Non-IFRS financial measures provided in this press release are useful to investors’ understanding and assessment of the Company’s performance. Management uses both IFRS and Non-IFRS measures when operating and evaluating the Company’s business internally and therefore decided to make these Non-IFRS adjustments available to investors. The presentation of this Non-IFRS financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. For further details, see a reconciliation of operating loss and net loss on an IFRS basis to a Non-IFRS basis that is provided in the table that accompanies this press release.

Over Itamar Medical Ltd.

Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. The Company’s key product, WatchPAT, is commercially available within major markets including the U.S., Japan and Europe. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. For example, when we discuss the 2021 revenue guidance range, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of Itamar Medical’s control and actual results, expressed or implied by such forward-looking statements, could differ materially from Itamar Medical’s current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by Itamar Medical in reports filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC) and the Israel Securities Authority (ISA), including the Company’s Annual Report on Form 20-F to be filed with the SEC, which is on file with the SEC (accessible at www.sec.gov) and the ISA. Except as otherwise required by law, Itamar Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contactpersoon Itamar Medical Investor Relations (VS)
Leigh Salvo
Gilmartin-groep
Telefoon: + 1-415-937-5412
investeerders@itamar-medical.com

* De inhoud van enige website of hyperlinks die in dit persbericht worden genoemd, zijn voor informatieve doeleinden en de inhoud daarvan maakt geen deel uit van dit persbericht.

ITAMAR MEDICAL LTD.
VERKORTE GECONSOLIDEERDE JAARREKENING VAN DE FINANCIËLE POSITIE
(Gecontroleerd)

	Maart 31, 2021			December 31, 2020

	Amerikaanse dollars in duizenden
Activa
Vlottende activa
Geldmiddelen en kasequivalenten	$	51,869		$	9,670
Bankdeposito's op korte termijn		27,000			30,000
Handelsvorderingen		8,269			8,354
Overige vorderingen		2,693			2,251
voorraden		7,146			7,164
Totaal vlottende activa		96,977			57,439

Vaste activa
Long-term restricted deposits and prepaid expenses		563			547
Handelsvorderingen op lange termijn		278			412
Onroerende zaken en uitrusting		3,245			2,904
Immateriële activa		3,206			1,037
Activa met gebruiksrecht		1,554			1,801
Totaal vaste activa		8,846			6,701
Totaal vermogen	$	105,823		$	64,140

Passiva
Kortlopende schulden
Banklening op korte termijn	$	5,000		$	5,000
Current maturities of long-term loan		135			135
Huidige looptijden van leaseverplichtingen		665			700
Handel verschuldigd		4,499			4,418
Overige schulden		4,266			5,973
Overlopende rekeningen		1,726			1,091
Voorzieningen		333			321
Personeelsbeloningen op korte termijn		613			354
Totaal kortlopende schulden		17,237			17,992

Langlopende verplichtingen
Langlopende lening		117			154
Langlopende leaseverplichtingen		1,106			1,380
Recognized liability for defined benefit plan, net		261			271
Overige langlopende schulden		1,271			1,271
Totaal langlopende verplichtingen		2,755			3,076
Totaal passiva		19,992			21,068

Billijkheid
Gewoon aandelenkapitaal		1,340			1,140
Extra volgestort kapitaal		207,469			161,006
Gecumuleerd tekort		(122,978	)		(119,074	)
Het totale eigen vermogen		85,831			43,072
Totaal passiva en eigen vermogen	$	105,823		$	64,140

ITAMAR MEDICAL LTD.
VERKORT GECONSOLIDEERDE VERKLARINGEN VAN ACTIVITEITEN
(Gecontroleerd)

	Drie maanden geleden Maart 31,
	2021			2020

	U.S. dollars in thousands (except per share and ADS data)

Inkomsten	$	11,977		$	8,378
Kosten van inkomsten		3,968			2,050
Brutowinst		8,009			6,328
Bedrijfskosten:
Verkoop en marketing		7,325			5,263
Onderzoek en ontwikkeling		2,889			1,302
Algemeen en administratief		3,091			1,720
Totale operationele kosten		13,305			8,285
Operationeel verlies		(5,296	)		(1,957	)
Financial income (expenses):
Financiële opbrengsten		146			235
Financiële uitgaven		(327	)		(234	)
Financiële inkomsten (kosten), netto		(181	)		1
Verlies vóór belastingen op inkomen		(5,477	)		(1,956	)
Belastingen op inkomen		(46	)		(42	)
Netto verlies	$	(5,523	)	$	(1,998	)

Loss per share – basic and diluted (in U.S. dollars)	$	(0.01	)	$	(0.01	)

Weighted average number of shares used in computation of loss per shares – basic and diluted (in thousands)		463,250			389,927

Loss per ADS – basic and diluted (in U.S. dollars)	$	(0.36	)	$	(0.15	)

Weighted average number of ADSs used in computation of loss per ADS – basic and diluted (in thousands)		15,442			12,998

ITAMAR MEDICAL LTD.
VERKORTE GECONSOLIDEERDE KASSTROOMOVERZICHTEN
(Gecontroleerd)

	Drie maanden geleden Maart 31,
	2021			2020

	Amerikaanse dollars in duizenden
Kasstroom uit operationele activiteiten
Netto verlies	$	(5,523	)	$	(1,998	)
Aanpassingen voor:
Afschrijvingen en amortisatie		758			410
Op aandelen gebaseerde betaling		1,620			362
Change in provision for doubtful and bad debt		(3	)		32
Net financial cost (income)		167			(97	)
Decrease in trade receivables		222			1,184
Afname (toename) van overige vorderingen		(469	)		228
Verhoging van voorraden		(133	)		(761	)
Toename handelsschulden		95			429
Decrease in other payables		(1,718	)		(1,292	)
Verhoging van voorzieningen		12			51
Increase in employee benefits		249			79
Winstbelastingen		46			42
Taxes paid during the period		(16	)		(1	)
Rente betaald tijdens de periode		(159	)		(147	)
Interest received during the period		54			73
Netto kasstroom uit operationele activiteiten		(4,798	)		(1,406	)
Kasstromen uit investeringsactiviteiten
Redemption of short-term bank deposits		3,000			-
Purchase of property and equipment, intangible assets, and capitalization of development expenditure		(2,274	)		(231	)
Netto contanten verstrekt door (gebruikt in) investeringsactiviteiten		726			(231	)
Kasstromen uit financieringsactiviteiten
Proceeds from issuance of shares, net of share issuance costs		46,660			37,061
Aflossing van de hoofdsom van leaseverplichtingen		(248	)		(225	)
Repayment of long-term loan		(33	)		-
Issuance of shares due to the exercise of stock options		4			-
Netto kasstroom uit financieringsactiviteiten		46,383			36,836
Toename van geldmiddelen en kasequivalenten		42,311			35,199
Geldmiddelen en kasequivalenten aan het begin van de periode		9,670			15,115
Effect of exchange rate fluctuations on balances of cash and cash equivalents		(112	)		128
Cash and cash equivalent balance at end of period	$	51,869		$	50,442

Non-cash investing activity – acquisition of intangible assets	$	600		$	-
Non-cash financing activity – share issuance costs	$	-		$	511

ITAMAR MEDICAL LTD.
RECONCILIATIONS OF IFRS TO NON-IFRS FINANCIAL MEASURES
(Gecontroleerd)

	Drie maanden geleden Maart 31,
	2021			2020

	U.S. dollars in thousands (except per ADS data)

IFRS operating loss	$	(5,296	)	$	(1,957	)
IFRS net loss	$	(5,523	)	$	(1,998	)

Kosten van inkomsten:
Op aandelen gebaseerde betaling		43			2
Depreciation and amortization of property and equipment and intangible assets		165			102
Non-recurring expenses related to relocating the Company’s production facilities to a new location		376			-
		584			104
Bedrijfskosten:
Selling and marketing:
Op aandelen gebaseerde betaling		643			119
Depreciation and amortization of property and equipment and intangible assets		34			31
		677			150
Onderzoek en ontwikkeling:
Op aandelen gebaseerde betaling		327			71
Depreciation and amortization of property and equipment and intangible assets		294			19
		621			90
General and administrative:
Op aandelen gebaseerde betaling		607			164
Depreciation and amortization of property and equipment and intangible assets		23			16
Change in provision for doubtful and bad debt		(3	)		32
		627			212
Financial income (expenses), net:
Op aandelen gebaseerde betaling		-			6
		-			6

Non-IFRS operating loss	$	(2,787	)	$	(1,401	)
Non-IFRS net loss	$	(3,014	)	$	(1,436	)

IFRS loss per ADS – basic and diluted (in U.S. dollars)	$	(0.36	)	$	(0.15	)

Non-IFRS loss per ADS – basic and diluted (in U.S. dollars)	$	(0.20	)	$	(0.11	)